Navigation Links
Actavis Plans Latin America Expansion
Date:10/5/2011

SUNRISE, Fla., Oct. 5, 2011 /PRNewswire/ -- Actavis Group CEO Claudio Albrecht today announced a major sales expansion into Latin America, among the world's fastest-growing markets for generic drugs.

Albrecht outlined the company's growth strategy at a meeting in South Florida with Actavis' new Latin American business unit. The Latin America team, based in Sunrise, Florida, will target Brazil, Argentina, Colombia, Mexico, Venezuela and other key markets in the region.  

With generic drugs not as widely used in South and Central America as in the United States and Europe, Albrecht said that Actavis' portfolio of nearly 900 lower-cost alternatives to brand medications represents a potential healthcare solution for millions. "This is not only a tremendous opportunity for Actavis to grow as a company, but also to bring great value to consumers while supporting better health," he said.

According to IMS Health, generic sales in Latin America grew by 14 percent from 2009 to 2010, compared to 4.4 percent worldwide. Generic sales in Latin America totalled $53.4 billion last year. Actavis Group, the world's fourth largest generic pharmaceutical company, already operates in more than 40 countries, and plans another major expansion in Japan.

The Latin America unit, headed by Ricardo Quirch, also includes specialists in regulatory affairs, portfolio and business development, supply-chain management and business administration. Quirch joined Actavis from Sandoz, the generics division of Novartis, most recently leading cross-divisional Asia-Pacific sourcing for the company.

"The decisions we are making now will have long-term benefits for health consumers in these countries," said Quirch. "We began with two products that we acquired several years ago and are now reviewing more than 20 products to potentially add to our portfolio, and in the process of receiving regulatory approval to begin marketing others."      

The Latin America unit is part of Actavis Inc., the global company's New Jersey-based U.S. subsidiary headed by U.S. CEO Doug Boothe.

About Actavis Inc.
Actavis Inc. is the U.S. subsidiary of Actavis Group hf. Approximately one third of Actavis' sales are generated in North America, Actavis' single largest market. Based in Morristown, NJ, Actavis has U.S. manufacturing and packaging facilities in Elizabeth, NJ; a manufacturing facility in Lincolnton, NC; research and development facilities in Owings Mills, MD and Sunrise, FL.; and a commercial development office in Sunrise, FL. Please visit www.actavis.us for more information.

About Actavis Group
Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. The company has operations in 40 countries, with more than 10,500 employees. Please visit www.actavis.com for more information.


'/>"/>
SOURCE Actavis
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis Launches Generic Keppra XR® Tablets in the U.S.
2. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
3. Actavis Launches Oxymorphone Hydrochloride Extended-Release Tablets, CII in the U.S.
4. Actavis Hails U.S. Supreme Court Decision in Labeling Cases
5. Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S.
6. Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S.
7. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
8. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
9. Actavis Encourages Consumers to Return Fentanyl Transdermal System 25 mcg/h
10. Actavis Inc. Issues a Voluntary Recall of 18 Lots of Fentanyl Transdermal System 25 mcg/h
11. Actavis Receives Approval of Zolpidem Tartrate Extended-Release Tablets, USP 6.25mg CIV in the U.S. with 180-Day Marketing Exclusivity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... -- Andre, DiMino, CEO of ADM Tronics Unlimited, Inc. (OTCQB: ... and products, commented on ADMT,s third quarter fiscal year ... the Company,s quarterly report on Form 10Q available at ... stated "During the quarter ended December 31, 2016 we ... portion of our engineering efforts into the development of ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... infarction partnering deals and agreements entered into by ... full report: http://www.reportlinker.com/p03605670-summary/view-report.html Description The ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
(Date:2/22/2017)... 22, 2017 Summary Provides ... partnering deals and agreements entered into by the ... report: http://www.reportlinker.com/p03605673-summary/view-report.html Description The Global ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
Breaking Medicine Technology:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... its certification exam and eligibility requirements effective with the April 2017 testing period. ... 1995. , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a ... skipping doses or not filling a prescription because they could not afford to ... problems getting medications were 30-60%*. At the same time, hospitals, pharmacies, ...
(Date:2/22/2017)... Colorado (PRWEB) , ... February ... ... the availability of their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” ... delivery system®, which provides instant absorption from the mouth into the bloodstream. ...
(Date:2/22/2017)... WV (PRWEB) , ... February 22, 2017 , ... ... awarded a contract to Quality Insights to help small practices in Delaware, New ... Payment Program, established by the Medicare Access and CHIP Reauthorization Act of 2015 ...
(Date:2/22/2017)... ... February 22, 2017 , ... Michael ... new media platform connecting healthcare technology professionals and other key stakeholders with an ... quarterly publication starting on March 1, announced Michael J. Hennessy, Jr., president of ...
Breaking Medicine News(10 mins):